What $108m?
Or do you always like to ignore operating costs and other current liabilities?
What of the US$1.8m to be paid within 60 days to note holders, or the October 2020 interest payment that combines with a US$7m+ amendment fee.
As a result of the 5% fee and delayed interest payment, the current debt to note holders is US$161m at a rate of 15%pa. That is up from the previous US$143m.
This financing deal is a solution to allow the company to continue to operate, not fund any of Stage 2.
I think at this point it is actually best to take the sage advise of o.c.16 and suggest you call AJM investor relations and get them to explain it to you.
My intention is not to contribute to FUD, but to clarify your comments that AJM now has $40m and can afford Stage 2.
I personally believe you are not intending to ramp, but could benefit from a call to the company because you will never take my word for it.
This refinancing and equity package is a great win for the company when you consider the alternative.
Good luck to you and have a nice weekend.
- Forums
- ASX - By Stock
- 1MC
- Opening on Monday
Opening on Monday, page-17
-
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1MC (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $18.53M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $3.621K | 1.257M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
121 | 181496973 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 20055545 | 43 |
Last trade - 15.53pm 04/07/2024 (20 minute delay) ? |
Featured News
1MC (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online